Smoldering plasma cell myeloma

Related records

Broader conditions (22)

• B-cell neoplasm
• Cancer
• Cancer or benign tumor
• Disease
• Disease by body system or component
• Disease by etiologic mechanism
• Hematologic disorder
• Hematopoietic and lymphoid cell neoplasm
• Hematopoietic and lymphoid system neoplasm
• Human disease
• Immune system cancer
• Immune system disorder
• Leukocyte disorder
• Lymphoid hemopathy
• Lymphoid neoplasm
• Lymphoma
• Myeloid neoplasm
• Neoplasm
• Neoplasm of mature B-cells
• Neoplastic disease or syndrome

Narrower conditions (1)

• Indolent plasma cell myeloma

Trials (104)

• A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
• A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)
• A Phase II Study of BI-505 in Smoldering Multiple Myeloma
• A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma
• A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma
• A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
• A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma
• A Prospective Multicenter Study of the Effects of Plant-based Diets on Gut Microbiome and Derived Metabolites in Patients Affected by Smoldering Multiple Myeloma
• A Real-world Study in Participants With Smoldering Multiple Myeloma
• A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
• A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma
• A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
• A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
• A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
• A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
• A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
• A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma
• A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
• A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma
• A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma

Drugs in development (28)

• Anakinra Phase 1
• Belantamab mafodotin Phase 1
• Bortezomib Phase 1
• Carfilzomib Phase 2
• Cholestyramine Phase 2
• Ciltacabtagene autoleucel Phase 2
• Daratumumab Phase 3
• Dexamethasone Phase 3
• Elotuzumab Phase 2
• Elranatamab Phase 2
• Hyaluronidase (human recombinant) Phase 3
• Iberdomide Phase 2
• Iberdomide hydrochloride Phase 2
• Incomplete freund'S adjuvant Phase 1
• Isatuximab Phase 2
• Ixazomib citrate Phase 2
• Leflunomide Phase 2
• Lenalidomide Phase 3
• Lenalidomide hydrochloride monohydrate Phase 3
• Linvoseltamab Phase 2